The U.S. FDA approved Myriad Genetics' MyChoice CDx Test as the companion diagnostic for GSK's PARP inhibitor Zejula in advanced ovarian cancer. The approval should increase Myriad's commercial testing volumes and reinforce its role in PARP therapy patient selection, supporting revenue potential tied to companion diagnostics. Expect a modest positive impact on MYGN shares, likely in the low single-digit percent range for the stock given the company- and sector-specific nature of the news.
The U.S. FDA approved Myriad Genetics' MyChoice CDx Test as the companion diagnostic for GSK's PARP inhibitor Zejula in advanced ovarian cancer. The approval should increase Myriad's commercial testing volumes and reinforce its role in PARP therapy patient selection, supporting revenue potential tied to companion diagnostics. Expect a modest positive impact on MYGN shares, likely in the low single-digit percent range for the stock given the company- and sector-specific nature of the news.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
